Overview of clinical trials in CML - Not yet recruiting trials
Source: www.clinicaltrials.gov | Last update: May 11, 2026
On this page, you'll find a regularly updated list of not yet recruiting clinical trials focused on novel therapies - including study details, sponsors, estimated enrolment, locations and the number of study centres.
Download our searchable Excel file to filter by sponsor, compound, or trial phase
(Updated regularly; the current file is from May 11, 2026)
For an overview of currently recruiting clinical trials in CML, click here.
Disclaimer
The information presented in this overview has been sourced from www.clinicaltrials.gov and reflects data available as of May 11, 2026. While the iCMLf strives to ensure accuracy, it is not responsible for any errors, updates, or changes that may have occurred since that date. This list is provided solely for informational purposes and is organized alphabetically by investigational compound. The iCMLf does not endorse or recommend any specific clinical trial, investigational drug, or sponsor mentioned. For the most current and comprehensive details - including eligibility criteria, study locations, and contact information - please consult the official listing on clinicaltrials.gov.
Asciminib
A Study on the tolerability, safety and effectiveness of Asciminib in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic-phase in Germany (ASC2ADHERE)
This study is a German real-world observational study evaluating the safety, tolerability, and effectiveness of asciminib in newly diagnosed or previously treated patients with Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia (Ph+ CML-CP).
More information
Clinicaltrials.gov Identifier: NCT07549516
Compound: Asciminib
Sponsor: Novartis Pharmaceuticals. novartis.email@novartis.com
Status: Not yet recruiting (estimated enrolment: 380 participants)
Location (Centres): Germany (exact site information not yet available)
Asciminib, with or without dasatinib combination, as a second-line therapy to ADVANCE the treatment for chronic myelogenous leukemia in chronic phase (ASC2ADVANCE)
The ASC2ADVANCE study evaluates whether asciminib alone or combined with dasatinib is an effective second-line treatment for chronic-phase chronic myeloid leukemia (CML-CP) patients whose first TKI therapy was unsuccessful or led to resistance. More information
Clinicaltrials.gov Identifier: NCT07538401
Compound: Asciminib
Sponsor: University Health Network, Toronto. dr.dennis.kim@uhn.ca
Status: Not yet recruiting (estimated enrolment: 45 participants)
Location (Centres): Location data not yet available
Pediatric CML Study
Study to determine the efficacy and safety of Asciminib in pediatric patients with Ph+ CML-CP
This phase II, multicenter, open-label, single-arm study evaluates the safety and efficacy of asciminib in pediatric patients with newly diagnosed or previously treated Philadelphia chromosome–positive CML in chronic phase, with or without the T315I mutation, including long-term follow-up for safety, growth, development, and treatment outcomes.
More information
Clinicaltrials.gov Identifier: NCT07354074
Compound: Asciminib
Sponsor: Novartis Pharmaceuticals. novartis.email@novartis.com
Status: Not yet recruiting (estimated enrolment: 50 participants)
Location (Centres): Location data not yet available
Real-world study of Scemblix (Asciminib) in the treatment of chronic myeloid leukemia in China
This multicenter, prospective, non-interventional real-world study evaluates the efficacy and safety of asciminib in patients with newly diagnosed chronic myeloid leukemia through systematic collection of baseline, treatment, and long-term follow-up data.
More information
Clinicaltrials.gov Identifier: NCT07375355
Compound: Asciminib
Sponsor: Novartis Pharmaceuticals. novartis.email@novartis.com
Status: Not yet recruiting (estimated enrolment: 200 participants)
Location (Centres): China (Exact location data not yet available)
HS-10382
Study of HS-10382 Combination in Patients With Chronic Myeloid Leukemia (CML)
This study aims to evaluate the efficacy of adding asciminib to tyrosine kinase inhibitors (TKIs) in achieving treatment-free remission (TFR) for chronic-phase CML patients who previously failed a TKI cessation study. More information
Clinicaltrials.gov Identifier: NCT06530810
Compound: HS-10382
Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd. dr_huyu@126.com
Status: Not yet recruiting (estimated enrolment: 100 participants)
Location (Centres): China (exact site information not yet available)
TGRX-678
TGRX-678 Chinese Phase III in chronic myeloid leukemia (CML) patients
This phase III randomized multicenter trial compares the safety and effectiveness of TGRX-678 versus investigator-selected TKI therapy in chronic-phase chronic myeloid leukemia (CML-CP) patients who are resistant or intolerant to at least three prior TKIs. More information
Clinicaltrials.gov Identifier: NCT07489755
Compound: TGRX-678
Sponsor: Shenzhen TargetRx Co., Ltd.
Status: Not yet recruiting (estimated enrolment: 180 participants)
Location (Centres): China (exact site information not yet available)
TQB3911
Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
Phase I clinical trial to explore the safety, tolerability, and initial efficacy of TQB3911 tablets in BCR::ABL fusion gene positive leukemia. More information
Clinicaltrials.gov Identifier: NCT06672263
Compound: TQB3911
Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. jiangqian@medmail.com.cn
Status: Not yet recruiting (estimated enrolment: 120 participants)
Location (Centres): China (5)